Welcome to our dedicated page for Alto Neuroscienc news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscienc stock.
Alto Neuroscience Inc (ANRO) is a new paradigm in mental health treatment, developing personalized therapies for depression and schizophrenia through neurobiological biomarkers. This page serves as the definitive source for verified updates about this clinical-stage biopharmaceutical innovator.
Investors and researchers will find essential information about ANRO's drug development pipeline, including clinical trial progress for assets like ALTO-100 and ALTO-300. Our curated news collection covers regulatory milestones, research partnerships, and scientific advancements in precision psychiatry.
Key updates include biomarker validation studies, FDA designations, and trial result analyses. All content undergoes strict verification to ensure alignment with financial disclosure standards and medical reporting best practices.
Bookmark this page for streamlined access to ANRO's latest developments in brain-based treatment innovation. Check regularly for authoritative updates on psychiatric drug development and personalized medicine breakthroughs.
Alto Neuroscience (NYSE: ANRO) has appointed Michael Hanley as its new Chief Operating Officer (COO). Hanley brings over 25 years of expertise in the life sciences industry, particularly in neuropsychiatric conditions like major depressive disorder and schizophrenia. His role will involve new product planning, portfolio strategy, and cross-functional leadership to enhance Alto's clinical-stage programs and biomarker platform. Hanley's extensive background includes leadership positions at Aeglea BioTherapeutics and Horizon Therapeutics. He holds a Bachelor of Business Administration from the University of Notre Dame and an MBA from Kellogg School of Management.
Alto Neuroscience (NYSE: ANRO) announced its Q1 2024 financial results and recent business updates. The company initiated a Phase 2 study of ALTO-203 for MDD and anhedonia, and reported positive Phase 1 data for the transdermal formulation of ALTO-101, showing improved drug exposure and tolerability. Patient enrollment for ALTO-100 and ALTO-300 Phase 2b MDD studies is progressing well. The company has a strong cash position of approximately $206 million, expected to support operations into 2027.
Alto's ongoing studies include ALTO-100 and ALTO-300, both targeting MDD, and ALTO-101 for CIAS. The company also announced the initiation of a Phase 2 proof-of-concept study for ALTO-203 in patients with MDD and high levels of anhedonia. Financial highlights include a net loss of $13.4 million, an increase in R&D expenses to $10 million, and higher G&A expenses reaching $4.4 million. Alto completed an upsized IPO in February 2024, netting $133 million in proceeds.
Alto Neuroscience, Inc. ('Alto') (ANRO) announced upcoming data presentations at the Society of Biological Psychiatry and American Society of Clinical Psychopharmacology Annual Meetings, showcasing its precision psychiatry pipeline. The company highlighted neurobiological markers linked to cognitive impairment in schizophrenia and the development of novel compounds for depression and schizophrenia. The ALTO-100 study identified memory-based cognitive markers predicting antidepressant response, while ALTO-101 showed significant effects on electrophysiological measures relevant to cognitive processing. ALTO-300 demonstrated EEG-based cognitive markers predicting greater response. The presentations aim to contribute to the scientific community and further develop treatment options for patients.
FAQ
What is the current stock price of Alto Neuroscienc (ANRO)?
What is the market cap of Alto Neuroscienc (ANRO)?
